The Obesity Clinic at Hospital General Tláhuac, Avenida la Turba # 655, Col. Villa Centroamericana y del Caribe, Delegación Tláhuac, 13250, Mexico, Mexico.
Obes Surg. 2021 Feb;31(2):544-553. doi: 10.1007/s11695-020-04920-7. Epub 2020 Aug 17.
Bariatric surgery is indicated for major weight loss and for the control of associated comorbidities, particularly type 2 diabetes. Remission prediction scores have been proposed for this end, such as: DiaRem, Ad-DiaRem, ABCD, and DiaBetter. Nevertheless, they have not been evaluated all together in a specific population.
Retrospective study with Mexican patients submitted to gastric bypass with at least 12 months follow-up. All patients had BMI > 30 kg/m and type 2 diabetes. The primary objective was to evaluate the remission prediction performance of scores. A baseline analysis (anthropometric, biochemical, and metabolic) and remission rates were obtained. Remission scores and cut-off values were assigned based on original descriptions. A ROC analysis was performed for sensibility and specificity.
A total of 95 patients were included. Mean age 44 years, 85.6% female with mean BMI of 44.1 kg/m, and mean HbA1C of 7.2%. At 12 months, complete remission was obtained in 76.8%. ROC curves were plotted showing that DiaRem had 75.3% sensitivity and 68.2% specificity (AUC 0.723 p = 0.001), Ad-DiaRem had 84.9% and 50% (AUC 0.702 p = 0.002), ABCD had 57.5% and 77.3% (AUC 0.0.690 p = 0.002), and DiaBetter had 72.6% and 77.3% (AUC 0.748 p < 0.001).
In Mexican patients with obesity and type 2 Diabetes, submitted to gastric bypass, remission prediction could be assessed with any current model showing satisfactory sensibility and specificity. Among such models, DiaBetter obtained the best statistical performance in our population. Type 2 diabetes remission rate at 1 year is similar to any other race or ethnicity.
减重手术适用于大幅减重和控制相关合并症,特别是 2 型糖尿病。为此已经提出了缓解预测评分,例如:DiaRem、Ad-DiaRem、ABCD 和 DiaBetter。然而,它们尚未在特定人群中进行综合评估。
对接受胃旁路手术且至少随访 12 个月的墨西哥患者进行回顾性研究。所有患者的 BMI>30kg/m2 且患有 2 型糖尿病。主要目的是评估评分的缓解预测性能。进行基线分析(人体测量、生化和代谢)和缓解率。根据原始描述分配缓解评分和截断值。进行 ROC 分析以评估敏感性和特异性。
共纳入 95 例患者。平均年龄 44 岁,85.6%为女性,平均 BMI 为 44.1kg/m2,平均 HbA1C 为 7.2%。在 12 个月时,76.8%的患者获得完全缓解。绘制 ROC 曲线显示,DiaRem 的敏感性为 75.3%,特异性为 68.2%(AUC 0.723,p=0.001),Ad-DiaRem 的敏感性为 84.9%,特异性为 50%(AUC 0.702,p=0.002),ABCD 的敏感性为 57.5%,特异性为 77.3%(AUC 0.690,p=0.002),DiaBetter 的敏感性为 72.6%,特异性为 77.3%(AUC 0.748,p<0.001)。
在接受胃旁路手术的肥胖和 2 型糖尿病墨西哥患者中,可以使用任何当前模型来评估缓解预测,这些模型均具有令人满意的敏感性和特异性。在这些模型中,DiaBetter 在我们的人群中获得了最佳的统计学性能。1 年后的 2 型糖尿病缓解率与其他任何种族或民族相似。